Target family: Coronavirus (CoV) proteins (type: other_protein)
Target: CoV Spike glycoprotein

Ligand: tixagevimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: EMA (2022)
Primary target: no
Median affinity:  -
Reference (Journal): Potently neutralizing and protective human antibodies against SARS-CoV-2.
Published in: Nature

Ligand: sotrovimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: UK & EMA (2021)
Primary target: no
Median affinity:  -

Ligand: SI5α-b (Peptide)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Computational design of ultrashort peptide inhibitors of the receptor-binding domain of the SARS-CoV-2 S protein.
Published in: Brief Bioinform

Ligand: regdanvimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: South Korea & EMA (2021)
Primary target: no
Median affinity: 10.569999694824219 pKd
Reference (Journal): A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein.
Published in: Nat Commun

Ligand: PiN-21 (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 12 pKd
Reference (Journal): Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2.
Published in: Science

Ligand: masavibart (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 9.920000076293945 pKd
Reference (Journal): ZRC3308 Monoclonal Antibody Cocktail Shows Protective Efficacy in Syrian Hamsters against SARS-CoV-2 Infection.
Published in: Viruses

Ligand: mAb 4A8 (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.03000020980835 pKd
Reference (Journal): A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
Published in: Science

Ligand: LCB3 (Peptide)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 9 pKd
Reference (Journal): De novo design of picomolar SARS-CoV-2 miniprotein inhibitors.
Published in: Science

Ligand: LCB1 (Peptide)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 9 pKd
Reference (Journal): De novo design of picomolar SARS-CoV-2 miniprotein inhibitors.
Published in: Science

Ligand: imdevimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: Japan, EMA and UK MHRA (2021)
Primary target: no
Median affinity: 9.640000343322754 pIC50
Reference (Journal): Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.
Published in: Science

Ligand: heparin (Metabolite)
Interaction type: None
Action: Binding
Ligand approved: yes
Approval source: FDA (1939)
Primary target: no
Median affinity: 10.140000343322754 pKd
Reference (Journal): Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions.
Published in: Antiviral Res

Ligand: heparin (Metabolite)
Interaction type: None
Action: Binding
Ligand approved: yes
Approval source: FDA (1939)
Primary target: no
Median affinity: 9 pKd
Reference (Journal): Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions.
Published in: Antiviral Res

Ligand: heparin (Metabolite)
Interaction type: None
Action: Binding
Ligand approved: yes
Approval source: FDA (1939)
Primary target: no
Median affinity: 6.300000190734863 pKd
Reference (Journal): Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions.
Published in: Antiviral Res

Ligand: etesevimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: ensovibep (Peptide)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Webpage): Molecular Partners pipeline page

Ligand: EK-1-C4 (Peptide)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.
Published in: Cell Res

Ligand: EK-1 (Peptide)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike.
Published in: Sci Adv

Ligand: CR3022 (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 8.199999809265137 pKd
Reference (Journal): Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.
Published in: Emerg Microbes Infect

Ligand: cilgavimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: EMA (2022)
Primary target: no
Median affinity:  -
Reference (Journal): Potently neutralizing and protective human antibodies against SARS-CoV-2.
Published in: Nature

Ligand: casirivimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: Japan, EMA and UK MHRA (2021)
Primary target: no
Median affinity: 10.15999984741211 pIC50
Reference (Journal): Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.
Published in: Science

Ligand: bebtelovimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants.
Published in: bioRxiv

Ligand: bamlanivimab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: alunacedase alfa (Peptide)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity:  -